Research Progress on TACE Combined with Targeted and Immunotherapy in the Comprehensive Treatment of Massive Hepatocellular Carcinoma
DOI:
https://doi.org/10.54097/d1kh6r13Keywords:
Massive Hepatocellular Carcinoma, Transarterial Chemoembolization, Targeted Therapy, ImmunotherapyAbstract
Massive hepatocellular carcinoma (HCC) is characterized by large tumor volume, strong invasiveness, high propensity for vascular invasion and intrahepatic dissemination. Consequently, most patients lose the opportunity of radical surgical resection at initial diagnosis. Monotherapy with conventional transarterial chemoembolization (TACE) is associated with low remission rate, high risk of recurrence and metastasis, and poor long-term survival. In recent years, the rapid development of targeted therapy and immunotherapy has provided novel systemic therapeutic approaches for advanced liver cancer. The comprehensive regimen of TACE combined with targeted and immunotherapy has gradually become a research hotspot for massive hepatocellular carcinoma. This article comprehensively reviews the mechanism and clinical application of TACE combined with targeted and immunotherapy in the treatment of patients with massive HCC, aiming to provide a reference for optimizing clinical treatment strategies for such patients.
Downloads
References
[1] Karunakaran, S., Ghanta, K. M., Cheetiyar, L. A., et al. (2025). Integrated therapies for targeting the microenvironment of hepatocellular carcinoma. Drug Discovery Today, 31(1), 104556. https://doi.org/10.1016/j.drudis.2025.104556.
[2] Lakshmikanthan, M., Muthu, S., & Caleb, D. T. J., et al. (2025). Liver cancer: Artificial intelligence (AI)-based integrated therapeutic approaches. Bioengineering, 12(8), 837. https:// doi. org/ 10.3390/bioengineering12080837.
[3] Xu, X., Zhang, X., Zhao, Y., et al. (2025). Comprehensive treatment of intermediate and advanced primary hepatocellular carcinoma based on transcatheter arterial chemoembolization (Review). Oncology Letters, 30(1), 332. https://doi.org/ 10. 3892/ ol.2025.13826.
[4] Zhong, D., Liang, Y., Yan, T. H., et al. (2025). A comparative study of five large language models' response for liver cancer comprehensive treatment. Journal of Hepatocellular Carcinoma, 12, 1861–1871. https://doi.org/ 10.2147/ JHC. S452963.
[5] Khan, M., & Begum, S. (2025). Integrated care for hepatocellular carcinoma: Patterns of presentation to a one-visit liver cancer clinic in a high HCV-burdened setting. HPB, 27(S2), S414. https://doi.org/10.1016/j.hpb.2025.03.764.
[6] Cordero, R. C., Molleda, C. G., Vera, G. J., et al. (2025). Multimodality treatment of metastatic hepatocellular carcinoma (BCLC-C). HPB, 27(S2), S449. https://doi.org/ 10. 1016/ j.hpb.2025.03.846.
[7] Goto, Y., Niizeki, T., Sakai, H., et al. (2024). A multidisciplinary therapeutic approach proposal for huge hepatocellular carcinomas exceeding 10 cm in diameter. Anticancer Research, 44(8), 3629–3636. https://doi.org/ 10. 21873/ anticanres.17164.
[8] Zhang, S., Li, N., Mao, X., et al. (2024). Effect of comprehensive nursing care for the liver cancer patients undergoing interventional therapy in China: A systematic review and meta-analysis. International Journal of Nursing Practice, 30(2), e13243. https://doi.org/10.1111/ijn.13243.
[9] Nidhi, G., & Shankar, P. (2023). Multidisciplinary approach for the management of hepatocellular carcinoma: Need of the hour. Cancer Research, Statistics, and Treatment, 6(4), 612–613. https://doi.org/10.4103/crst.crst_138_23.
[10] Zhang, Y., & Yao, Z. (2023). Comprehensive bioinformatics analysis reveals PTPN1 (PTP1B) is a promising immunotherapy target associated with T cell function for liver cancer. Journal of Healthcare Engineering, 2023, 1533794. https:// doi.org/10.1155/2023/1533794.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
